Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation-Reference-Cited by-同舟云学术

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation

Published:2015-11-27 Issue:4 Volume:21 Page:286-294
ISSN:1083-4389
Container-title:Helicobacter
language:en
Short-container-title:Helicobacter

Author:

Mori Hideki¹,Suzuki Hidekazu²,Matsuzaki Juntaro¹,Tsugawa Hitoshi³,Fukuhara Seiichiro¹,Miyoshi Sawako¹,Hirata Kenro¹,Seino Takashi¹,Matsushita Misako¹,Masaoka Tatsuhiro¹,Kanai Takanori¹

Affiliation:

1. Division of Gastroenterology and Hepatology; Department of Internal Medicine; Keio University School of Medicine; Tokyo Japan

2. Medical Education Center; Keio University School of Medicine; Tokyo Japan

3. Department of Biochemistry and Integrative Medical Biology; Keio University School of Medicine; Tokyo Japan

Funder

Grant-in-Aid for Young Scientists

Grant-in-Aid for Scientific Research B

Grant-in-Aid for challenging Exploratory Research

Japan Society for the Promotion of Science

Strategic Research Foundation at Private Universities

Princess Takamatsu Cancer Research

Smoking Research Foundation

Takeda Science Foundation

Keio Gijuku Academic Development Funds

Astellas Pharma US

Otsuka Pharmaceutical

Takeda Pharmaceutical Company

Zeria Pharmaceutical Co., Ltd.

Eisai Pharmaceutical Co., Ltd.

Tanabe Mitsubishi Pharmaceutical Co., Ltd.

JIMRO Co., Ltd.

Kyorin Pharmaceutical Co. Ltd.

Miyarisan Pharmaceutical Co. Ltd.

Publisher

Wiley

Subject

Infectious Diseases,Gastroenterology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hel.12286/fullpdf

Reference42 articles.

1. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology;Soll;JAMA,1996

2. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial;Fukase;Lancet,2008

3. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma;Wotherspoon;Lancet,1991

4. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients;Asaka;Helicobacter,2001

5. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance;Murakami;Aliment Pharmacol Ther,2003

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species;Frontiers in Cellular and Infection Microbiology;2024-08-29

2. Single-Arm, Prospective, Interventional Study of Helicobacter pylori Eradication Rescue Therapy with Rifabutin, Metronidazole, and Vonoprazan;Journal of Clinical Medicine;2024-06-27

3. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori;Journal of Clinical Medicine;2023-08-22

4. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review;World Journal of Gastroenterology;2023-01-14

5. Fluoroquinolone and Rifabutin-Containing Therapy;Helicobacter pylori;2023